Graham Capital Management’s Seres Therapeutics MCRB Stock Holding History

Graham Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-15,469	Closed	-$239K	–	1231
2024 Q1	$239K	Buy	15,469 +7,404	+92%	+$160K	﹤0.01%	852
2023 Q4	$226K	Sell	8,065 -2,277	-22%	-$59.8K	0.01%	805
2023 Q3	$492K	Buy	10,342 +9,098	+731%	+$694K	0.01%	568
2023 Q2	$119K	Buy	+1,244	New	+$135K	﹤0.01%	878
2022 Q4	–	Sell	-5,307	Closed	-$681K	–	1206
2022 Q3	$681K	Sell	5,307 -7,120	-57%	-$729K	0.03%	639
2022 Q2	$852K	Buy	12,427 +7,058	+131%	+$608K	0.03%	492
2022 Q1	$764K	Sell	5,369 -102	-2%	-$15.7K	0.03%	400
2021 Q4	$911K	Buy	+5,471	New	+$869K	0.04%	102

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Graham Capital Management's MCRB Position: Q2 2024 in Review

Graham Capital Management sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 15,469 shares — an estimated $239K sold.

Graham Capital Management first reported a position in MCRB in Q4 2021 and held it in 8 quarters. The position peaked at $911K in Q4 2021. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.

Graham Capital Management reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
Graham Capital Management sold 15,469 Seres Therapeutics shares in Q2 2024, an estimated $239K.
Graham Capital Management first reported a position in Seres Therapeutics in Q4 2021 and held it in 8 quarters.
Graham Capital Management's Seres Therapeutics position peaked at $911K in Q4 2021.
93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.

Based on Graham Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.